Results 131 to 140 of about 18,746 (183)

Computational Identification of Potent Multitarget Natural Ligands for Alzheimer's Disease Therapeutics. [PDF]

Scientifica (Cairo)
Sharif N, Bibi A, Sadiq R, Ullah I, Rauf A, Arshad MT, Bashir S, Zamir H, Gull S, Anwar T, Laryea E.   +10 more
europepmc   +1 more source

Quality of life evidence for patients with Alzheimer's disease : Use of existing quality of life evidence from the ADENA trials to estimate the utility impact of Exelon® (Appendix 1 - Utility evidence) [PDF]

Brazier, J.
core  

Add-On Pharmacotherapy in Schizophrenia: Does It Improve Long-Term Outcomes? A Systematic Review. [PDF]

J Clin Med
Smyrnis A, Smyrnis G, Smyrnis N.
europepmc   +1 more source

Current pharmacologic options for patients with Alzheimer's disease [PDF]

William E Reichman
core   +1 more source

Patterns and predictors of cholinesterase inhibitor use in dementia with Lewy bodies. [PDF]

Alzheimers Dement (N Y)
Heo RJ, Negida A, Wyman-Chick KA, Bateman JR, Rodriguez-Porcel F, Berman BD, Mukhopadhyay N, Barrett MJ.   +7 more
europepmc   +1 more source

Repurposed Arylidene-hydrazinyl-1,3-thiazoles as Multitarget Anti-Alzheimer's Agents via Combined Computational and Experimental Studies. [PDF]

ACS Omega
Drozdowska D, Ratkiewicz A, Wróbel-Tałałaj A, Parzych C, El-Dershaby HA, Abd El-Razik HA, Soliman FSG, El-Wakil MH.   +7 more
europepmc   +1 more source

Persistence with anti-dementia medications: a systematic review and meta-analysis. [PDF]

Age Ageing
Sistanizad M, Peterson GM, Ling T, Salahudeen MS, Akondi VM, Bezabhe WM.   +5 more
europepmc   +1 more source

Thymol carbamates bearing cyclic amines as potent and selective BuChE inhibitors alleviate memory impairments for Alzheimer's disease therapy. [PDF]

J Enzyme Inhib Med Chem
Wu C, Ding Y, Liu X, Gao S, Wang X, Tang W.   +5 more
europepmc   +1 more source